GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jacobio Pharmaceuticals Group Co Ltd (HKSE:01167) » Definitions » ROC %

Jacobio Pharmaceuticals Group Co (HKSE:01167) ROC % : -108.87% (As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Jacobio Pharmaceuticals Group Co ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Jacobio Pharmaceuticals Group Co's annualized return on capital (ROC %) for the quarter that ended in Jun. 2024 was -108.87%.

As of today (2025-04-10), Jacobio Pharmaceuticals Group Co's WACC % is 11.42%. Jacobio Pharmaceuticals Group Co's ROC % is -65.09% (calculated using TTM income statement data). Jacobio Pharmaceuticals Group Co earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Jacobio Pharmaceuticals Group Co ROC % Historical Data

The historical data trend for Jacobio Pharmaceuticals Group Co's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jacobio Pharmaceuticals Group Co ROC % Chart

Jacobio Pharmaceuticals Group Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROC %
Get a 7-Day Free Trial 170.11 -195.62 -246.08 -127.58 -64.58

Jacobio Pharmaceuticals Group Co Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -336.77 -146.43 -104.57 -108.87 -9.15

Jacobio Pharmaceuticals Group Co ROC % Calculation

Jacobio Pharmaceuticals Group Co's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=-446.511 * ( 1 - 0% )/( (282.146 + 417.797)/ 2 )
=-446.511/349.9715
=-127.58 %

where

Invested Capital(A: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1758.431 - 155.328 - ( 1433.413 - max(0, 174.041 - 1494.998+1433.413))
=282.146

Invested Capital(A: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1597.443 - 126.031 - ( 1250.327 - max(0, 224.367 - 1277.982+1250.327))
=417.797

Jacobio Pharmaceuticals Group Co's annualized Return on Capital (ROC %) for the quarter that ended in Jun. 2024 is calculated as:

ROC % (Q: Jun. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Jun. 2024 ))/ count )
=-410.276 * ( 1 - 0% )/( (417.797 + 335.885)/ 2 )
=-410.276/376.841
=-108.87 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1597.443 - 126.031 - ( 1250.327 - max(0, 224.367 - 1277.982+1250.327))
=417.797

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1413.245 - 108.984 - ( 1136.27 - max(0, 193.501 - 1161.877+1136.27))
=335.885

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Jacobio Pharmaceuticals Group Co  (HKSE:01167) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Jacobio Pharmaceuticals Group Co's WACC % is 11.42%. Jacobio Pharmaceuticals Group Co's ROC % is -65.09% (calculated using TTM income statement data). Jacobio Pharmaceuticals Group Co earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Jacobio Pharmaceuticals Group Co ROC % Related Terms

Thank you for viewing the detailed overview of Jacobio Pharmaceuticals Group Co's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Jacobio Pharmaceuticals Group Co Business Description

Traded in Other Exchanges
Address
No. 88, Kechuang 6th Street, Building F2, Beijing Economic-Technological Development Area, Beijing, CHN
Jacobio Pharmaceuticals Group Co Ltd is a clinical-stage pharmaceutical company focusing on the in-house discovery and development of innovative oncology therapies.
Executives
Qiming Corporate Gp Vi, Ltd. 2201 Interest of corporation controlled by you
Qiming Venture Partners Vi, L.p. 2101 Beneficial owner
Qiming Gp Vi, L.p. 2201 Interest of corporation controlled by you
Wang Yinxiang 2501 Other
Wang Xiaojie 2307 Founder of a discretionary trust who can infl
Hu Yunyan 2501 Other
Hillhouse Investment Management, Ltd. 2102 Investment manager
Hillhouse Fund Iv, L.p. 2201 Interest of corporation controlled by you
Hh Spr-iii Holdings Limited 2101 Beneficial owner
Shen Zhu 2501 Other
Ultimate Estate Limited 2201 Interest of corporation controlled by you
Treasure Partner International Limited 2501 Other
Gloryviewpharma Ltd 2501 Other
Honourpharma Ltd 2501 Other
Blesspharma Ltd 2501 Other

Jacobio Pharmaceuticals Group Co Headlines

No Headlines